文献速递核素与放射性配体治疗

神经内分泌肿瘤肽受体放射性核素治疗的剂量学方法与临床应用:文献综述

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review.
PubMed 文献 · EJNMMI Res · 2018-08-29

该文献综述通过PubMed检索纳入288篇原创文章,讨论PRRT治疗神经内分泌肿瘤中最重要的剂量学方法、优缺点及临床意义,并概述临床研究中的剂量学应用。结论认为PRRT临床剂量学可行且可改善治疗结果,当前研究聚焦安全性并采用非体素剂量学方法,使用精细剂量学方法评估肿瘤与正常组织摄取以实现个体化治疗是下一步方向。

要点

  • PRRT是转移性神经内分泌肿瘤可接受的全身放射性核素治疗方案,但剂量学尚未常规开展。
  • 综述纳入288篇原创文章,梳理了PRRT剂量学方法、优缺点及临床意义。
  • 当前临床剂量学研究聚焦安全性,采用非体素剂量学方法。

核心结论

  • PRRT中的临床剂量学是可行的,并可改善治疗结果。
  • 当前临床剂量学研究聚焦安全性并应用非体素剂量学方法。
  • 在临床试验中使用精细剂量学方法评估肿瘤和正常组织摄取以实现个体化治疗,是PRRT常规剂量学的下一步。

研究设计与样本

  • 文献综述,通过PubMed检索剂量学、辐射剂量、肽受体放射性核素治疗和放射性核素治疗相关文献,按标题和摘要及剂量学方法描述筛选,共纳入288篇原创文章。

主要发现

  • 综述讨论了最重要的剂量学方法、其主要优缺点及临床环境中的意义。
  • 综述概述了PRRT治疗神经内分泌肿瘤临床研究中的剂量学应用。

局限性

  • 原文指出PRRT中剂量学尚未常规开展,主要原因是文献证据缺乏和临床实施困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy response and decrease toxicity after SRT by individual treatment planning. Peptide receptor radionuclide therapy (PRRT) is an accepted SRT treatment option for irresectable and metastatic neuroendocrine tumours (NET). However, dosimetry in PRRT is not routinely performed, mainly due to the lack of evidence in literature and clinical implementation difficulties. The goal of this review is to provide insight in dosimetry methods and requirements and to present an overview of clinical aspects of dosimetry in PRRT for NET. METHODS: A PubMed query including the search criteria dosimetry, radiation dose, peptide receptor radionuclide therapy, and radionuclide therapy was performed. Articles were selected based on title and abstract, and description of dosimetric approach. RESULTS: A total of 288 original articles were included. The most important dosimetry methods, their main advantages and limitations, and implications in the clinical setting are discussed. An overview of dosimetry in clinical studies regarding PRRT treatment for NET is provided. CONCLUSION: Clinical dosimetry in PRRT is feasible and can result in improved treatment outcomes. Current clinical dosimetry studies focus on safety and apply non-voxel-based dosimetry methods. Personalised treatment using sophisticated dosimetry methods to assess tumour and normal tissue uptake in clinical trials is the next step towards routine dosimetry in PRRT for NET.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Huizing DMV, de Wit-van der Veen BJ, Verheij M, et al. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 2018. PMID: 30159614. doi:10.1186/s13550-018-0443-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。